¼¼°èÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç° Á¾·ùº°, ±â¼úº°, Àü´Þ ¹æ¹ýº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
CRISPR And Cas Genes Market, By Product Type, By Technology, By Delivery Method, By Therapeutic Area, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1756406
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 301 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,474,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,401,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,778,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå ±Ô¸ð´Â 2024³â 47¾ï 129¸¸ ´Þ·¯·Î 2025³âºÎÅÍ 2032³â±îÁö CAGR 16.50%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå ¿ªÇÐ

Á¤¹Ð À¯ÀüÀÚ ÆíÁýÀÇ ¹ßÀüÀ¸·Î ½ÃÀå ¼ºÀå °¡¼ÓÈ­

ƯÈ÷ CRISPR ¹× Cas À¯ÀüÀÚ¸¦ Æ÷ÇÔÇÑ Á¤¹Ð À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀüÀº Àü ¼¼°èÀûÀ¸·Î ¿¬±¸¿Í Ä¡·á¿¡ÀÇ Àû¿ëÀ» Å©°Ô °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)¿¡ µû¸£¸é, À¯ÀüÀÚ ÆíÁý ÀÓ»ó½ÃÇèÀÇ 70% ÀÌ»óÀÌ ÇöÀç CRISPR-Cas ½Ã½ºÅÛÀÇ Á¤È®¼º°ú È¿À²¼ºÀ¸·Î ÀÎÇØ CRISPR-Cas ½Ã½ºÅÛ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ÃÖ±Ù ÀÌ·¯ÇÑ ÅøÀ» Ȱ¿ëÇÑ À¯ÀüÀÚ Ä¡·áÁ¦¸¦ ½ÂÀÎÇߴµ¥, ÀÌ´Â ±ÔÁ¦ ´ç±¹ÀÇ ¼ö¿ëÀÌ ÁøÇàµÇ°í ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù. ¶ÇÇÑ, Àΰ£ À¯Àüü ÇÁ·ÎÁ§Æ®¿Í °°Àº ¼¼°è ÀÌ´Ï¼ÅÆ¼ºê´Â À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀÌÇØ¸¦ Áö¼ÓÀûÀ¸·Î È®´ëÇÏ¿© Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Ç¥Àû ¿Ü È¿°ú¿Í À±¸®Àû °í·Á »çÇ×°ú °°Àº °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖÀ¸¸ç, ¾ÈÀü¼º°ú Àü´ÞÀ» °³¼±ÇÒ ¼ö ÀÖ´Â ±â¼ú Çõ½ÅÀÇ ±âȸ¸¦ ¿­¾îµÎ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Á¤¹Ð À¯ÀüÀÚ ÆíÁýÀÌ º¹ÀâÇÑ À¯ÀüÀû ÁúȯÀ» ÇØ°áÇÏ°í ¸ÂÃãÇü ÀǷḦ ¹ßÀü½ÃŰ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖ´Â ¿ªµ¿ÀûÀÎ »óȲÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 16.50%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â 2024³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù

±â¼ú ±âÁØÀ¸·Î 2024³â¿¡´Â CRISPR/Cas9°¡ ÁÖ¿ä ±â¼úÀ̾ú½À´Ï´Ù.

Àü´Þ ¹æ¹ýº°·Î´Â ¹ÙÀÌ·¯½º º¤ÅͰ¡ 2024³â ÁÖ¿ä Àü´Þ ¹æ¹ýÀ̾ú½À´Ï´Ù.

Ä¡·á ºÐ¾ßº°·Î´Â 2024³â¿¡´Â ¾Ï ºÐ¾ß°¡ ÁÖ¿ä Ä¡·á ¿µ¿ªÀ̾ú½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é 2024³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ´Â »ý¸í°øÇÐ ¹× Á¦¾àȸ»ç¿´½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÍ¿øÀÔ´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº Á¦Ç° À¯Çü, ±â¼ú, Àü´Þ ¹æ¹ý, Ä¡·á ¿µ¿ª, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° Á¾·ù¿¡ µû¶ó µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Á¦Ç°(ŰƮ ¹× ½Ã¾à, ¶óÀ̺귯¸®), ¼­ºñ½º(¹Ì»ý¹° À¯ÀüÀÚ ÆíÁý, ¼¼Æ÷ÁÖ ¿£Áö´Ï¾î¸µ, gRNA ¼³°è ¹× ÇÕ¼º, DNA ÇÕ¼º, ½ºÅ©¸®´× ¼­ºñ½º, ±âŸ)ÀÔ´Ï´Ù. Á¦Ç° ºÎ¹®Àº Cas ´Ü¹éÁú°ú °¡À̵å RNA¸¦ Æ÷ÇÔÇÑ Å°Æ® ¹× ½Ã¾àÀÌ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, µðÀÚÀÎ Åø°ú Ç×ü¸¦ Ư¡À¸·Î ÇÏ´Â ¶óÀ̺귯¸®°¡ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¼­ºñ½º ºÎ¹®Àº ¹Ì»ý¹° À¯ÀüÀÚ ÆíÁý, ¼¼Æ÷ÁÖ ¿£Áö´Ï¾î¸µ, gRNA µðÀÚÀÎ, DNA ÇÕ¼º, ½ºÅ©¸®´×¿¡ ÁßÁ¡À» µÎ°í Àü ¼¼°è¿¡ Á¾ÇÕÀûÀÎ À¯ÀüÀÚ ÆíÁý ¿öÅ©Ç÷ο츦 Áö¿øÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ±â¼úº°·Î CRISPR/Cas9, CRISPR/Cas12, CRISPR/Cas13, ±âŸ µî ¼¼ °¡Áö ¹üÁÖ·Î ³ª´µ¸ç, CRISPR/Cas9´Â Á¤¹Ð À¯ÀüÀÚ ÆíÁý ÀÀ¿ë ºÐ¾ß¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖÀ¸¸ç, Áø´Ü ¹× Ä¡·á¿¡ »ç¿ëµÇ´Â CRISPR/Cas12°¡ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. CRISPR/Cas13Àº RNA Ÿ°ÙÆÃ¿¡ ƯȭµÇ¾î ÀÖÀ¸¸ç, ±× ¿Ü Àü ¼¼°è ¿¬±¸ ¹× ÀÓ»ó ºÐ¾ß¿¡¼­ ¿ª·®À» È®ÀåÇÏ´Â ½ÅÈï º¯ÀÌüµéÀÌ ÀÖ½À´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº° ºÐ¼®

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº źźÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í Á¤ºÎ Áö¿ø¿¡ ÈûÀÔ¾î ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ Ȱ¹ßÇÑ È°µ¿À» º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ¹Ì±¹ ±¹¸³º¸°Ç¿ø(National Institutes of Health)°ú °°Àº ±â°üÀÇ ¸·´ëÇÑ ÀÚ±Ý Áö¿ø°ú º¸½ºÅϰú »÷ÇÁ¶õ½Ã½ºÄÚ¿Í °°Àº ÁÖ¿ä »ý¸í°øÇÐ ÇãºêÀÇ Á¸Àç·Î ÀÎÇØ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µîÀÇ ±¹°¡µéÀÌ À¯·´¿¬ÇÕÀÇ È£¶óÀÌÁð ÇÁ·Î±×·¥ÀÇ Áö¿øÀ» ¹Þ¾Æ À¯ÀüÀÚ ÆíÁý ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ Áß±¹, ÀϺ», Çѱ¹¿¡¼­ ±Þ¼ºÀåÇϰí ÀÖÀ¸¸ç, »ý¸í°øÇп¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÏ°í ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ±â¼ú Çõ½Å°ú »ó¿ëÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ÀÇ ½ÅÈï ½ÃÀå¿¡¼­´Â ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß¿¡ À¯ÀüÀÚ ÆíÁý ±â¼úÀ» µµÀÔÇϱ⠽ÃÀÛÇßÁö¸¸ ±× ¼Óµµ´Â ´À¸®Áö¸¸, CRISPR ¹× Cas À¯ÀüÀÚÀÇ ¼¼°è ¹ßÀÚÃë´Â ¼¼°è Çù¾÷°ú ÇмúÀû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ´õ¿í °­È­µÇ°í ÀÖÀ¸¸ç, ½ÃÀå ¹ßÀü¿¡ ÀÖ¾î Áö¿ªÀû Àü¹® Áö½Ä°ú ÀÚ¿øÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. Áö½Ä°ú ÀÚ¿øÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : °æÀï ±¸µµ

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀÇ °æÀï ±¸µµ´Â À¯ÀüÀÚ ÆíÁý ±â¼ú °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ÁÖ¿ä »ý¸í°øÇÐ ±â¾÷, Çмú ±â°ü, Çõ½ÅÀû ½ºÅ¸Æ®¾÷¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖÀ¸¸ç, Editas MedicineÞä, CRISPR TherapeuticsÞä, Intellia Therapeutics µî ÁÖ¿ä ±â¾÷µéÀº µ¶ÀÚÀûÀÎ CRISPR-Cas Ç÷§ÆûÀ» Àû±ØÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, Àü·«Àû Á¦ÈÞ ¹× ¶óÀ̼±½º °è¾àÀ» ÅëÇØ ±â¼ú·ÂÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. Çмú¿¬±¸¼¾ÅÍ´Â »õ·Î¿î Cas º¯ÀÌüÀÇ ¹ß°ß°ú Àü´Þ ¹æ¹ýÀÇ °³¼±À¸·Î ±â¼ú Çõ½Å¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿°±â ÆíÁý ¹× ÇÁ¶óÀÓ ÆíÁý°ú °°Àº Æ´»õ ±â¼úÀ» °¡Áø ½Å»ý ±â¾÷µµ µîÀåÇÏ¿© Á¤È®µµ¸¦ ³ôÀÌ°í ¿ÀÇÁ Ÿ°Ù È¿°ú¸¦ °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ÁöÀûÀç»ê±ÇÀº Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÇöÀç ÁøÇà ÁßÀΠƯÇã ºÐÀïÀº °æÀï ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Á¦¾à ȸ»ç ¹× ¿¬±¸ ±â°ü°úÀÇ Á¦ÈÞ´Â Ä¡·á¹ý °³¹ß ¹× »ó¾÷È­ ³ë·ÂÀ» °¡¼ÓÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ È®Àå °¡´ÉÇÑ »ý»ê°ú »ý¹°Á¤º¸ÇÐ µµ±¸ÀÇ °³¼±À» À§ÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ·Î °æÀïÀÌ ½ÉÈ­µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå CRISPR ¹× Cas À¯ÀüÀÚÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå »óȲ

Á¦7Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç° Á¾·ùº°

Á¦8Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ±â¼úº°

Á¦9Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Àü´Þ ¹æ¹ýº°

Á¦10Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Ä¡·á ºÐ¾ßº°

Á¦11Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº°

Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® : CRISPR ¹× Cas À¯ÀüÀÚ ¾÷°è

Á¦14Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

CRISPR And Cas Genes Market size was valued at US$ 4,701.29 Million in 2024, expanding at a CAGR of 16.50% from 2025 to 2032.

The CRISPR and Cas Genes Market involves advanced gene-editing technologies used for precise genetic modifications across research, therapeutic, and agricultural applications. Increasing adoption of gene-editing tools for developing personalized medicine and disease-resistant crops boosts innovation, while challenges like ethical concerns and regulatory hurdles limit rapid growth. Growing investments in genetic research have led to a surge in CRISPR patent filings, with over 3,000 patents recorded by major institutions globally. Opportunities lie in expanding applications in rare genetic disorders and regenerative medicine, supported by initiatives from organizations like the National Institutes of Health (NIH), promoting genome editing research. However, complexities in delivery methods and off-target effects pose restraints, underscoring the need for improved accuracy and safety in gene-editing practices.

CRISPR And Cas Genes Market- Market Dynamics

Advancements in Precision Gene Editing to Accelerate Market Growth

Advancements in precision gene editing technologies, particularly involving CRISPR and Cas genes, are significantly accelerating research and therapeutic applications worldwide. According to the National Institutes of Health (NIH), over 70% of gene-editing clinical trials currently focus on CRISPR-Cas systems due to their accuracy and efficiency. The U.S. Food and Drug Administration (FDA) has recently approved several gene therapies utilizing these tools, reflecting growing regulatory acceptance. Furthermore, global initiatives like the Human Genome Project continue to expand understanding of genetic diseases, fueling demand for precise gene-editing solutions. However, challenges such as off-target effects and ethical considerations persist, opening opportunities for innovations that improve safety and delivery. These advancements are fostering a dynamic landscape where precision gene editing plays a pivotal role in addressing complex genetic disorders and advancing personalized medicine.

CRISPR And Cas Genes Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.50% over the forecast period (2025-2032)

Based on product type segmentation, the Product was predicted to show maximum market share in the year 2024

Based on Technology segmentation, CRISPR/Cas9 was the leading Technology in 2024

Based on Delivery Method segmentation, Viral Vectors were the leading Delivery Method in 2024

Based on Therapeutic Area segmentation, Oncology was the leading Therapeutic Area in 2024

Based on end user segmentation, Biotechnology & Pharmaceutical Companies were the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

CRISPR And Cas Genes Market- Segmentation Analysis:

The Global CRISPR and Cas Genes Market is segmented on the basis of Product Type, Technology, Delivery Method, Therapeutic Area, End User, and Region.

The market is divided into two categories based on product type: Product (Kits & Reagents and Libraries), and Service (Microbial Gene Editing, Cell Line Engineering, gRNA Design & Synthesis, DNA Synthesis, Screening Services, and Others). Product segment leads with Kits & Reagents, including Cas Proteins and Guide RNA, followed by Libraries featuring design tools and antibodies. Services focus on microbial gene editing, cell line engineering, gRNA design, DNA synthesis, and screening, supporting comprehensive gene-editing workflows globally.

The market is divided into three categories based on Technology: CRISPR/Cas9, CRISPR/Cas12, CRISPR/Cas13, and Others. CRISPR/Cas9 dominates with precise gene editing applications, followed by CRISPR/Cas12 used in diagnostics and therapeutics. CRISPR/Cas13 specializes in RNA targeting, while others include emerging variants expanding capabilities across research and clinical settings worldwide.

CRISPR And Cas Genes Market- Geographical Insights

The CRISPR and Cas Genes market shows strong activity across North America, Europe, and Asia-Pacific, driven by robust research infrastructure and government support. North America leads due to substantial funding from agencies like the National Institutes of Health and the presence of leading biotech hubs such as Boston and San Francisco. Europe follows closely, with countries like Germany, the UK, and France advancing gene-editing research through initiatives supported by the European Union's Horizon programs. Asia-Pacific is rapidly growing, especially in China, Japan, and South Korea, where increasing investments in biotechnology and supportive regulatory frameworks are fostering innovation and commercialization. Emerging markets in Latin America and the Middle East are beginning to adopt gene-editing technologies for healthcare and agricultural applications, although at a slower pace. Collaborative efforts and academic partnerships worldwide are further strengthening the global footprint of CRISPR and Cas genes, highlighting the importance of regional expertise and resource availability in advancing the market.

CRISPR And Cas Genes Market- Competitive Landscape:

The competitive landscape of the CRISPR and Cas Genes market is shaped by key biotechnology companies, academic institutions, and innovative startups focusing on advancing gene-editing technologies. Major players such as Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics are actively developing proprietary CRISPR-Cas platforms, with strategic collaborations and licensing agreements expanding their technological capabilities. Academic research centers contribute significantly by discovering new Cas variants and improving delivery methods, fueling innovation. Startups are also emerging with niche technologies, including base editing and prime editing, enhancing precision and reducing off-target effects. Intellectual property rights play a critical role, with ongoing patent disputes influencing competitive dynamics. Partnerships with pharmaceutical companies and research organizations accelerate therapeutic development and commercialization efforts. Additionally, investment in R&D for scalable production and improved bioinformatics tools is intensifying competition, as firms strive to meet growing demand across therapeutic and agricultural applications globally.

Recent Developments:

In November 2024, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR/Cas9-based gene editing therapy, CASGEVY, for sickle cell disease and transfusion-dependent beta thalassemia, marking a major milestone in the clinical application of CRISPR and Cas gene technologies.

In August 2024, CRISPR QC launched three innovative products-RNP Formation, DNA Target Binding, and CLEAVE-within its CRISPR Analytics Platform, offering real-time insights into CRISPR/Cas gene editing workflows. These tools optimize efficiency, accuracy, and quality control for gene editing research and therapeutic development.

In January 2025, Researchers at Aarhus University unveiled a triple-action CRISPR technology enabling simultaneous gene activation, repression, and deletion in primary human T cells. This breakthrough uses multiple CRISPR/Cas systems, advancing complex genetic engineering for cell therapy and regenerative medicine applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRISPR AND CAS GENES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL CRISPR AND CAS GENES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENES MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENES MARKET, BY DELIVERY METHOD- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENES MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. CRISPR And Cas Genes Market Overview

2. Executive Summary

3. CRISPR And Cas Genes Key Market Trends

4. CRISPR And Cas Genes Industry Study

5. CRISPR And Cas Genes Market: Impact of Escalating Geopolitical Tensions

6. CRISPR And Cas Genes Market Landscape

7. CRISPR And Cas Genes Market - By Product Type

8. CRISPR And Cas Genes Market - By Technology

9. CRISPR And Cas Genes Market - By Delivery Method

10. CRISPR And Cas Genes Market - By Therapeutic Area

11. CRISPR And Cas Genes Market - By End User

12. CRISPR And Cas Genes Market- By Geography

13. Key Vendor Analysis- CRISPR And Cas Genes Industry

14. 360 Degree Analyst View

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â